Aveanna Healthcare Holdings announced that certain selling stockholders, including affiliates of J.H. Whitney Equity Partners VII and current and former directors and officers, have commenced a secondary offering of 15 million shares of common stock. The underwriter has a 30-day option to purchase up to an additional 2.25 million shares. The selling stockholders will receive all net proceeds from the offering. Aveanna is not offering any shares and will not receive any proceeds from the sale. RBC Capital Markets will serve as the sole book-running manager for the offering. Atlanta-based Aveanna Healthcare operates in 39 states, providing paediatric and adult healthcare services primarily focused on home care, including nursing, hospice, rehabilitation, and therapy for medically complex and chronically ill patients.

Aveanna Healthcare Holdings has reported strong Q1 2026 results, with revenue reaching $647.9 million, up 15.9% year-over-year. Net income surged to $41.7 million from $5.2 million in the prior-year period, whilst Adjusted EBITDA grew 25.2% to $84.4 million. The home care services provider maintains solid liquidity with $189.3 million in cash and substantial undrawn borrowing capacity. Growth was driven across all three major business segments as the company works towards finalising its Family First Homecare acquisition. Following this momentum, Aveanna has raised its full-year 2026 guidance, expecting total revenue between $2.56 and $2.58 billion and Adjusted EBITDA of $328 to $332 million. The company's shares trade under $10 on NASDAQ.

Aveanna Healthcare reported first-quarter earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.13 per share and marking its fourth consecutive quarterly earnings surprise. The result represents a 35.85% surprise and compares to $0.10 per share a year ago. The home healthcare services provider posted revenues of $647.92 million for the quarter ended March 2026, surpassing estimates by 5.11% and up from $559.22 million in the year-ago period. This marks the third time in four quarters the company has exceeded revenue expectations. Despite the strong results, Aveanna shares have declined 17.1% year-to-date, underperforming the S&P 500's 8.8% gain. The company currently holds a Zacks Rank of 2 (Buy), suggesting expected near-term market outperformance.